RxDoctor Payments Data

Amy Shaver

Acute Care · North Chesterfield, VANPI 1134545239

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,629in general payments, 2019–2025

Across 339 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$787
  • AstraZeneca$763
  • Incyte Corporation$448
  • Johnson & Johnson$350
  • Genentech USA, Inc.$294
  • Astellas Pharma US Inc$284
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,01692%
  • Education$6138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis36$787
AstraZeneca34$763
Incyte Corporation17$448
Johnson & Johnson23$350
Genentech USA, Inc.11$294
Astellas Pharma US Inc10$284
Pfizer13$258
Eisai Inc.13$258
Merck13$254
Amgen8$233
Ipsen Biopharmaceuticals, Inc8$189
Sanofi-aventis U.S. LLC2$182
Daiichi Sankyo Inc.8$163
EMD Serono, Inc.8$161
Bayer7$161
Sanofi7$153
Karyopharm Therapeutics Inc.7$152
AbbVie6$125
Regeneron Healthcare Solutions, Inc.6$124
Exelixis Inc.2$121
Taiho Oncology, Inc.5$113
Legend Biotech USA Inc.5$110
Collegium Pharmaceutical, Inc.2$109
Takeda Pharmaceuticals U.S.A., Inc.5$109
Gilead(2 entities)3$79
Beone Medicines USA, Inc.3$79
Rigel Pharmaceuticals, Inc.4$78
Seagen Inc.4$77
Pharmacyclics LLC, An Abbvie Company4$77
E.r. Squibb & Sons, L.L.C.4$69
Pharmacosmos Therapeutics Inc.3$67
Lilly USA, LLC3$65
Mirati Therapeutics, Inc.3$64
Sobi, Inc3$62
ADC Therapeutics America, Inc.4$62
Caris MPI, Inc.3$60
Array Biopharma Inc3$60
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$54
Tersera Therapeutics LLC2$54
Stemline Therapeutics Inc.2$52
Servier Pharmaceuticals LLC3$49
Azurity Pharmaceuticals, Inc.2$48
GRT US Holding, Inc.1$45
Kyowa Kirin, Inc.2$42
Adaptive Biotechnologies Corporation2$41
Bristol Myers Squibb2$40
G1 Therapeutics, Inc.2$40
Boehringer Ingelheim2$33
AVEO Pharmaceuticals, Inc.2$32
Genmab U.S., Inc.2$32
Celltrion USA Inc.1$26
GSK1$26
Geron Corporation1$25
Impel Pharmaceuticals Inc.1$23
Jazz Pharmaceuticals Inc.1$21
Beigene USA, Inc.1$20
Morphosys, US Inc.1$19
Coherus Oncology, Inc.1$18
Novocure Inc.1$17
Iovance Biotherapeutics, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,629 in reported general payments places this provider in the 95th percentile of 599 acute care providers in Virginia.

See all acute care providers in Virginia

Medicare billing

Part B allowed, 2024
$32,039
Medicare patients
132
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fentanyl148$17,501
Xtampza ErOxycodone Myristate19$16,126
Oxycodone Hcl253$7,336
Hydromorphone ErHydromorphone Hcl11$3,735
Hydromorphone Hcl61$1,765
Naloxone Hcl27$1,648
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$1,341
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$798
Mirtazapine40$757
Morphine Sulfate ErMorphine Sulfate20$407
Dexamethasone22$339
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$286
Gabapentin32$274
Pregabalin14$273
Escitalopram Oxalate14$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$109$16,12619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 599 acute care providers in Virginia.

Other acute care in North Chesterfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →